Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells

被引:36
作者
Sudan, Sudhanshu [1 ]
Rupasinghe, H. P. Vasantha [1 ,2 ]
机构
[1] Dalhousie Univ, Fac Agr, Dept Environm Sci, Truro, NS B2N 5E3, Canada
[2] Dalhousie Univ, Fac Med, Dept Pathol, Halifax, NS B3H 4RN, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Quercetin-3-O-glucoside; acylation; cancer; apoptosis; cell cycle; caspase-3; topoisomerase II; HepG2; cells; hepatocellular carcinoma; chemotherapy; CYCLE ARREST; QUERCETIN; APOPTOSIS; CANCER; INHIBITION; FLAVONOIDS; CYTOTOXICITY; ACTIVATION; EXPRESSION; PROTEIN;
D O I
10.1177/1535370215570828
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Despite their strong role in human health, poor bioavailability of flavonoids limits their biological effects in vivo. Enzymatically catalyzed acylation of fatty acids to flavonoids is one of the approaches of increasing cellular permeability and hence, biological activities. In this study, six long chain fatty acid esters of quercetin-3-O-glucoside (Q3G) acylated enzymatically and were used for determining their antiproliferative action in hepatocellular carcinoma cells (HepG2) in comparison to precursor compounds and two chemotherapy drugs (Sorafenib and Cisplatin). Fatty acid esters of Q3G showed significant inhibition of HepG2 cell proliferation by 85 to 90% after 6h and 24h of treatment, respectively. The cell death due to these novel compounds was associated with cell-cycle arrest in S-phase and apoptosis observed by DNA fragmentation, fluorescent microscopy and elevated caspase-3 activity and strong DNA topoisomerase II inhibition. Interestingly, Q3G esters showed significantly low toxicity to normal liver cells than Sorafenib (P<0.05), a chemotherapy drug for hepatocellular carcinoma. Among all, oleic acid ester of Q3G displayed the greatest antiproliferation action and a high potential as an anti-cancer therapeutic. Overall, the results of the study suggest strong antiproliferative action of these novel food-derived compounds in treatment of cancer.
引用
收藏
页码:1452 / 1464
页数:13
相关论文
共 38 条
[1]   Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition [J].
Agullo, G ;
GametPayrastre, L ;
Manenti, S ;
Viala, C ;
Remesy, C ;
Chap, H ;
Payrastre, B .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) :1649-1657
[2]  
Arts ICW, 2001, INT J CANCER, V92, P298, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1187>3.0.CO
[3]  
2-8
[4]   Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2) [J].
Belen Granado-Serrano, Ana ;
Angeles Martin, Maria ;
Bravo, Laura ;
Goya, Luis ;
Ramos, Sonia .
JOURNAL OF NUTRITION, 2006, 136 (11) :2715-2721
[5]   Cell death independent of caspases:: A review [J].
Bröker, LE ;
Kruyt, FAE ;
Giaccone, G .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3155-3162
[6]   Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest [J].
Cheong, E ;
Ivory, K ;
Doleman, J ;
Parker, ML ;
Rhodes, M ;
Johnson, IT .
CARCINOGENESIS, 2004, 25 (10) :1945-1952
[7]  
Choi JA, 2001, INT J ONCOL, V19, P837
[8]   Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis [J].
Coss, Alan ;
Tose, Miriam ;
Fox, Edward J. ;
Sapetto-Rebow, Beata ;
Gorman, Sheeona ;
Kennedy, Breanddn N. ;
Lloyd, Andrew T. ;
Hyland, John M. ;
O'Donoghue, Diarmuid P. ;
Sheahan, Kieran ;
Leahy, Dermot T. ;
Mulcahy, Hugh E. ;
O'Sullivan, Jacintha N. .
CANCER LETTERS, 2009, 276 (02) :228-238
[9]  
El-Awady RA, 2008, SAUDI MED J, V29, P558
[10]   Quercetin and Cancer Chemoprevention [J].
Gibellini, Lara ;
Pinti, Marcello ;
Nasi, Milena ;
Montagna, Jonas P. ;
De Biasi, Sara ;
Roat, Erika ;
Bertoncelli, Linda ;
Cooper, Edwin L. ;
Cossarizza, Andrea .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2011, 2011 :1-15